The Secreted Metabolite Isopentenyladenine from Faecalibacterium prausnitzii Mitigates Gut Inflammation

Abstract

Colonic microbiome dysbiosis is correlated with inflammatory bowel disease (IBD), and depletion of the commensal bacterium Faecalibacterium prausnitzii (F. prausnitzii) is routinely observed in the metagenomic analyses of IBD patient microbiome samples. F. prausnitzii is likely beneficial to hosts, as oral administration of F. prausnitzii strain A2-165 has anti-inflammatory properties in murine models of colitis. Previous studies attribute the anti-inflammatory effects of F. prausnitzii A2-165 to production of the short-chain fatty acid butyrate, as well as a 15 kDa protein known as microbial anti-inflammatory molecule (MAM). Here, we verified that oral dosing of strain A2-165 protects against DSS-induced murine colitis and further show the aqueous-soluble secreted fraction of overnight cultures from a collection of F. prausnitzii strain inhibit inflammatory signatures, including the activation of the hosts NF-{kappa}B pathway, production of IL-8, and differentiation of naive T cells into the TH17 lineage. We find that MAM is secreted in extracellular vesicles; however, MAM-containing vesicles do not have anti-inflammatory properties in our collection of assays and suggests that MAM is likely not a direct contributor. Untargeted and targeted mass spectrometry metabolomics analyses on the soluble anti-inflammatory secretome yielded several unique F. prausnitzii metabolites, including isopentenyladenine. We demonstrated isopentenyladenine independently modulates host cellular signaling and immune responses and suggests this newly identified metabolite with human immunomodulatory properties may be useful towards the discovery of IBD-focused therapeutics.